Clinical trials: Endocrine Disorders
Diabetes Mellitus, Type 2
A Study to Test How New Long-acting Insulin (Insulin Icodec) Works in the Body of Children and Teenagers
Insulin icodec is a new medicine which is under development for use in humans and is not yet available at the pharmacy. It is being developed for the treatment of diabetes, a condition that causes high blood sugar levels.
- Trial name
- NCT05790681
- Testing
- Insulin icodec
- Where
- 21 sites in United States
- Volunteers
- 18 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Observational Study of Biphasic Insulin Aspart 30 Alone or in Combination With Oral Hypoglycaemic Agents in Subjects With Type 2 Diabetes
This study is conducted in Africa, Asia and Europe. The aim of this study is to investigate biphasic insulin aspart 30 (NovoMix® 30) alone or in combination with oral hypoglycaemic agent (OHA) for type 2 diabetes management in…
- Trial name
- PRESENT (NCT01536600)
- Testing
- biphasic insulin aspart 30
- Where
- South Korea
- Volunteers
- 33,010 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
Omarigliptin (MK-3102) Clinical Trial - Add-on to Oral Antihyperglycemic Agent Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-3102-015)
This study will examine the safety and efficacy of the addition of omarigliptin in Japanese participants with type 2 diabetes mellitus who have inadequate glycemic control on diet/exercise therapy and oral antihyperglycemic agent…
- Trial name
- NCT01697592
- Testing
- Omarigliptin
- Volunteers
- 585 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 1
A Comparative Study of LY900014 With Insulin Lispro (Humalog) in Participants With Type 1 Diabetes Mellitus
The purpose of this study is to evaluate a new formulation of insulin lispro, LY900014, which is a drug that lowers blood sugar.
- Trial name
- NCT03341299
- Testing
- LY900014, Insulin Lispro
- Where
- 2 sites in Germany
- Volunteers
- 36 people
- Sponsor
- Eli Lilly and Company
Diabetes, Diabetes Mellitus, Type 2
GAPP 2 Survey: Global Attitudes of Patients and Physicians in Insulin Therapy for Type 2 Diabetes Mellitus
This study is conducted Asia, Europe and North America. The aim of this study is to describe insulin therapy adherence and the burden of non-adherence on patient functioning, well-being and diabetes management.
- Trial name
- NCT01950637
- Testing
- No treatment given, survey
- Where
- 6 sites in United States, Canada and 4 more
- Volunteers
- 4,000 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Evaluation of Pharmacokinetics and Safety of AJU-A51 in Healthy Adults
To evaluate the safety and pharmacokinetic characteristics of AJU-A51 in healthy adults
- Trial name
- NCT04972539
- Testing
- AJU-A51 Tab., A51R1 Tab. and A51R2 Tab.
- Where
- South Korea
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- AJU Pharm Co., Ltd.
Diabetes, Diabetes Mellitus, Type 2
Dose-response, Safety and Efficacy of Oral Semaglutide Versus Placebo and Versus Liraglutide, All as Monotherapy in Japanese Subjects With Type 2 Diabetes
This trial is conducted in Asia. The aim of this trial is to investigate the dose-response relationship of once-daily dosing of three dose levels (3, 7 and 14 mg) of oral semaglutide versus placebo as monotherapy on glycaemic…
- Trial name
- PIONEER 9 (NCT03018028)
- Testing
- Semaglutide, Liraglutide
- Where
- 16 sites in Japan
- Volunteers
- 243 people
- Sponsor
- Novo Nordisk A/S
Breast Cancer
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
The purpose of this study is to learn about the safety and effects of the study medicine PF-07248144 when given along with fulvestrant for the possible treatment of HR-positive, HER2-negative advanced or metastatic breast cancer.
- Trial name
- NCT07062965
- Testing
- PF-07248144, Fulvestrant, Everolimus
- Where
- 433 sites in United States, Argentina and 29 more
- Volunteers
- 400 people
- Sponsor
- Pfizer
Postmenopausal Women With Advanced Breast Cancer
Study of Safety and Efficacy of Letrozole Monotherapy as Second-line Endocrine Therapy in Postmenopausal Patients With Advanced Breast Cancer Who Received Previous Anti-estrogen Treatment
Safety and efficacy of letrozole 2.5 mg/day monotherapy as second-line endocrine therapy in postmenopausal patients with advanced breast cancer who received previous anti-estrogen treatment To investigate changes in blood drug…
- Trial name
- NCT00237198
- Testing
- Letrozole
- Where
- 24 sites in Japan
- Volunteers
- 47 people
- Sponsor
- Novartis Pharmaceuticals
Diabetes
Pilot Usability Study to Set Up and Use the Feetsee™ Foot Monitoring Device in Adults With Diabetes
Single-center, prospective, minimal-risk, non-experimental usability study assessing the setup and use of the FDA-registered (Class I medical device; 510(k)-exempt) Feetsee™ home foot-monitoring system by adults with diabetes in…
- Trial name
- NCT07666087
- Testing
- Pilot Usability Study to Set Up and Use the Feetsee™ Foot Monitoring Device
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Diabetis JSC
Diabetes, Type 1, Diabetes, Type 2
Safety of Inhaled Insulin With Type 1 and Type 2 Diabetes
Pulmonary Safety in Diabetics with T/I
- Trial name
- NCT00308737
- Testing
- Technosphere® Insulin Inhalation Powder, Usual Care
- Where
- 176 sites in United States, Canada and 6 more
- Volunteers
- 2,053 people, healthy volunteers welcome
- Sponsor
- Mannkind Corporation
Diabetes Mellitus, Type 2
A Study to Test How Insulin NNC0471-0119 H Works in the Body in Participants With Type 2 Diabetes When Given by an Insulin Pump
This study looks at the effect and safety of a new fast-acting insulin (NNC0471-0119) in people with type 2 diabetes when given by an insulin pump.
- Trial name
- NCT07068295
- Testing
- NNC0471-0119 H, Insulin Aspart
- Where
- Germany
- Volunteers
- 65 people
- Sponsor
- Novo Nordisk A/S
Advanced or Metastatic Solid Tumors
A Dose Escalation/Expansion Study of MDK-703 in Patients With Advanced or Metastatic Solid Tumors
This is an open-label, dose escalation and dose expansion study of MDK-703 as a monotherapy and in combination with other cancer therapies in adult study participants with advanced or metastatic solid tumors.
- Trial name
- ORCHID-1 (NCT05716295)
- Testing
- MDK-703, Checkpoint Inhibitor, Immune
- Where
- 6 sites in United States
- Volunteers
- 26 people
- Sponsor
- Medikine, Inc.
Diabetes Mellitus, Type 2
The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial)
The purpose of this study is to evaluate the efficacy and safety of canagliflozin compared with sitagliptin and placebo in patients with type 2 diabetes mellitus who are receiving treatment with metformin monotherapy (i.e.…
- Trial name
- NCT01106677
- Testing
- Canagliflozin, Sitagliptin, Metformin immediate release
- Where
- 125 sites in United States, Argentina and 20 more
- Volunteers
- 1,284 people
- Sponsor
- Janssen Research & Development, LLC
Hypoparathyroidism
A Study to Investigate the Safety and Tolerability of NPSP558, for the Treatment of Adults With Hypoparathyroidism - A Clinical Extension Study in Hungary
This study is designed to evaluate the effect of 6-months of treatment with NPSP558 in reducing requirements for supplemental oral calcium and active vitamin D, while maintaining stable total serum calcium levels in adult…
- Trial name
- REPEAT (NCT01455181)
- Testing
- NPSP558
- Where
- 3 sites in Hungary
- Volunteers
- 24 people
- Sponsor
- Shire
Type 2 Diabetes
Efficacy and Safety of Metformin Glycinate Compared to Metformin Hydrochloride on the Progression of Type 2 Diabetes
Phase III study to evaluate the efficacy and safety of the treatment. Two-arm, prospective, longitudinal, double-blind, multicenter randomized clinical trial.
- Trial name
- COMETII (NCT04943692)
- Testing
- Metformin glycinate, Metformin Hydrochloride
- Where
- Mexico
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Laboratorios Silanes S.A. de C.V.
Ovarian Cancer
An Efficacy and Safety Study of MORAb-003 in Platinum-Resistant or Refractory Relapsed Ovarian Cancer
The study is being conducted to find out if paclitaxel works better when given together with an experimental drug called MORAb-003 (farletuzumab) or alone in patients with platinum-resistant or refractory relapsed ovarian cancer
- Trial name
- FAR-122 (NCT00738699)
- Testing
- MORAb-003 (farletuzumab), 0.9% Saline, Paclitaxel
- Where
- 61 sites in United States, Australia and 4 more
- Volunteers
- 415 people
- Sponsor
- Morphotek
Diabetes Mellitus, Type 2
A Study Comparing Subcutaneous Rapid Acting Insulin and One Formulation of Inhaled Insulin in Subjects With Type 2 Diabetes
The original protocol was a randomized, open-label, 3-way cross-over study with 9 scheduled visits. The visits comprised an initial screening visit, 3 treatment visits for the meal challenge followed by a 2-6-week blood-loss…
- Trial name
- NCT00570687
- Testing
- Technosphere Insulin
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Mannkind Corporation
Diabetic Foot Ulcer, Diabetic Foot
Evaluation of DIAMEL® Combined With Insulin in Diabetic Foot Ulcer
Diabetic foot syndrome is one of the most frequent complications in type 2 diabetic patients. The present work is carried out with the objective of evaluating the use of DIamel combined with insulin in diabetic foot ulcers.
- Conditions
- Diabetic Foot Ulcer, Diabetic Foot, Diabetes Mellitus, Type 2
- Trial name
- NCT03583593
- Testing
- DIAMEL
- Where
- Cuba
- Volunteers
- 100 people
- Sponsor
- Catalysis SL
Type 2 Diabetes Mellitus
Study To Investigate The Safety And Metabolism Of GSK376501 In Overweight Subjects
This study represents the second Phase 1 study with GSK376501 and the goal is to further evaluate its safety and tolerability. The way the human body processes GSK376501 will also be determined.
- Trial name
- NCT00495014
- Testing
- GSK376501
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline